- Home
- GTBP vs BCAB Comparison
GTBP vs BCAB Comparison
Compare GTBP & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTBP | BCAB |
|---|---|---|
| Founded | 1965 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1M | 12.5M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GTBP | BCAB |
|---|---|---|
| Price | $0.41 | $0.15 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 648.3K | ★ 1.2M |
| Earning Date | 03-02-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.75 | ★ 44.19 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $0.13 |
| 52 Week High | $3.73 | $1.43 |
Technical Indicators
Market Signals| Indicator | GTBP | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 39.08 | 43.00 |
| Support Level | $0.40 | $0.15 |
| Resistance Level | $0.59 | $0.21 |
| Average True Range (ATR) | 0.03 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 23.79 | 21.05 |
Price Performance
Historical ComparisonAbout GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.